RxDoctor Payments Data

Charles Woods, MD

Ophthalmology · Decatur, ALNPI 1396748786

Payments from drug & device makers

$2,997in general payments, 2019–2025

Across 134 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$594
  • Johnson & Johnson Surgical Vision, Inc.$304
  • Ocular Therapeutix, Inc.$254
  • Sun Pharmaceutical Industries Inc.$191
  • Oyster Point Pharma, Inc.$100
  • plus $429 from 9 others

What the payments were for

  • Food & beverage$2,68590%
  • Education$401%
  • Gifts$452%
  • Entertainment$973%
  • Other$1304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,997 in reported general payments places this provider in the 65th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$499,462
Medicare patients
1,658
Services billed
3,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost262$98,020
RestasisCyclosporine102$77,893
Cyclosporine99$60,450
RhopressaNetarsudil Mesylate87$35,328
RocklatanNetarsudil Mesylat/Latanoprost87$34,960
SimbrinzaBrinzolamide/Brimonidine Tart134$33,732
MieboPerfluorohexyloctane/Pf30$22,376
Latanoprost1,739$21,171
XiidraLifitegrast15$20,176
CombiganBrimonidine Tartrate/Timolol57$17,307
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol82$15,826
Travoprost86$15,648
Brimonidine Tartrate374$12,625
Prednisolone Acetate202$10,911
Alphagan PBrimonidine Tartrate29$8,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,125$202,119450 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$18$49,08759 claims
AlconSimbrinza$594$33,732134 claims
Oyster Point Pharma, Inc.Tyrvaya$100$7,85412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →